Be The Match BioTherapies® and Tmunity Announce Collaboration to Support Clinical Trials of Next-Generation Immunotherapies
Partnership will accelerate access to novel therapeutics for patients with devastating diseases
MINNEAPOLIS and PHILADELPHIA, July 9, 2019—Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company, today announced a partnership to accelerate patient access to life-saving cell therapies.
The collaboration leverages Be The Match BioTherapies’ industry-leading cell therapy supply chain and collection network management expertise to support clinical development of Tmunity’s diversified portfolio of novel treatments, that exhibit best-in-class control over T cell activation and direction in the body. These personalized next-generation immunotherapies for cancer are advancing through preclinical and clinical testing.
“It’s an exciting moment for Tmunity as we widen our clinical pipeline of investigational immunotherapies to address a broad range of solid tumor and hematological cancers—and Be The Match BioTherapies is the ideal partner to help advance that work,” said Usman “Oz” Azam, MD, President and Chief Executive Officer of Tmunity. “We look forward to working together to deliver powerful new options for patients and to bring about the future of cell therapy.”
Be The Match BioTherapies will support Tmunity’s ongoing work to advance T-cell immunotherapies. These efforts will include the management of cell therapy supply chain and logistics, supported by the company’s MatchSource® Supply Chain Software. In addition, Be The Match BioTherapies will qualify, develop and train a network of collection centers to help ensure the collection of consistent, compliant and high-quality cell starting material. To gain efficiencies in site qualification, Tmunity will receive licensed access to quality system audit results through the Quality System Audit Program (QSAP).
“Be The Match BioTherapies was built to empower the development and delivery of next-generation cell and gene therapies like those being developed by Tmunity,” said Chris McClain, MBA, vice president, Sales and New Business Development, Be The Match BioTherapies. “We are eager to help speed access to Tmunity’s innovative therapies for patients in need.”
About Be The Match BioTherapies
Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program®/Be The Match®, and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance cell and gene therapies in any stage of development.
Be The Match BioTherapies is dedicated to providing high-quality cellular starting material consented for research, clinical and commercial use, developing and managing expansive cell collection networks, and navigating cell therapy regulatory compliance. Using proven infrastructure to successfully manage cell therapy supply chains, including MatchSource® Supply Chain Software, personalized case managers and logistics experts, the organization has a history of compliance managing the chain of identity. The collaboration with CIBMTR extends services to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.
About Tmunity Therapeutics
Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer and two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in East Norriton, Penn., to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.
Be The Match BioTherapies:
Ten Bridge Communications
Lisa Raffensperger, (617) 903-8783
Lisa A. Hayes
VP, Investor Relations and Corporate Communications